Alethio Therapeutics raises $90 million Series A to develop antibody for essential thrombocythemia

Alethio Therapeutics, a spinout from the University of Oxford, announced a $90 million Series A financing round.

The capital will fund the company’s lead program, an antibody designed to treat essential thrombocythemia, a rare blood cancer.

The raise comes about a year after Alethio emerged from stealth, highlighting investor confidence in its approach.

CEO Rohit Batta said the funding will accelerate development and bring the therapy closer to patients.